BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 1764165)

  • 1. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Antoniw P; Bagshawe KD; Wilman DE
    Anticancer Drug Des; 1991 Nov; 6(5):467-79. PubMed ID: 1764165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ
    J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
    J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
    Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
    Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
    Springer CJ; Niculescu-Duvaz I; Pedley RB
    J Med Chem; 1994 Jul; 37(15):2361-70. PubMed ID: 8057284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems.
    Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ
    J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
    Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH
    Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Bavetsias V; Jackman AL; Boyle FT; Marshall D; Pedley RB; Bisset GM
    Anticancer Drug Des; 1996 Dec; 11(8):625-36. PubMed ID: 9022750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link.
    Dowell RI; Springer CJ; Davies DH; Hadley EM; Burke PJ; Boyle FT; Melton RG; Connors TA; Blakey DC; Mauger AB
    J Med Chem; 1996 Mar; 39(5):1100-5. PubMed ID: 8676345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody directed enzyme prodrug therapy (ADEPT): clinical report.
    Bagshawe KD; Sharma SK; Springer CJ; Antoniw P; Boden JA; Rogers GT; Burke PJ; Melton RG; Sherwood RF
    Dis Markers; 1991; 9(3-4):233-8. PubMed ID: 1813213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.
    Springer CJ; Antoniw P; Bagshawe KD; Searle F; Bisset GM; Jarman M
    J Med Chem; 1990 Feb; 33(2):677-81. PubMed ID: 2299634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
    Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ
    Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Lehouritis P; Marais R; Springer CJ
    J Med Chem; 2003 Apr; 46(9):1690-705. PubMed ID: 12699387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
    Springer CJ; Niculescu-Duvaz I
    Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
    Blakey DC; Valcaccia BE; East S; Wright AF; Boyle FT; Springer CJ; Burke PJ; Melton RG; Bagshawe KD
    Cell Biophys; 1993; 22(1-3):1-8. PubMed ID: 7889535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug.
    Spooner RA; Martin J; Friedlos F; Marais R; Springer CJ
    Cancer Gene Ther; 2000 Oct; 7(10):1348-56. PubMed ID: 11059693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.
    Monks NR; Blakey DC; Curtin NJ; East SJ; Heuze A; Newell DR
    Br J Cancer; 2001 Sep; 85(5):764-71. PubMed ID: 11531265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.
    Antoniw P; Springer CJ; Bagshawe KD; Searle F; Melton RG; Rogers GT; Burke PJ; Sherwood RF
    Br J Cancer; 1990 Dec; 62(6):909-14. PubMed ID: 2257218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT).
    Monks NR; Calvete JA; Curtin NJ; Blakey DC; East SJ; Newell DR
    Br J Cancer; 2000 Jul; 83(2):267-9. PubMed ID: 10901381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.